Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amanda Flohr

Physician Assistant, Medical Pasadena, TX Physician Assistant

NPI 1205491594 CMS profile 11046324

4102 Woodlawn Ave Ste 110, Pasadena, TX 77504

Open in the dashboard

General payments

$17,731

678 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Flohr of Pasadena, TX is reported in the CMS Open Payments database as having received $17,731 across 678 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,486 90
2024 General $3,612 129
2023 General $3,418 169
2022 General $5,436 153
2021 General $2,779 137

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Flohr
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Amanda Flohr were reported at $2,486. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Amanda Flohr Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,779 $156 $41–$563 $132
2022 $5,436 $185 $55–$649 $149
2023 $3,418 $199 $58–$717 $160
2024 $3,612 $206 $62–$740 $164
2025 $2,486 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Mannkind Corporation $3,005 26 payments
  2. Novo Nordisk Inc $1,778 88 payments
  3. Dexcom, Inc. $1,436 48 payments
  4. Corcept Therapeutics $1,114 49 payments
  5. Lilly USA, LLC $1,026 61 payments
  6. Amgen Inc. $768 36 payments
  7. Horizon Therapeutics plc $702 20 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $671 31 payments
  9. Xeris Pharmaceuticals, Inc. $603 32 payments
  10. Radius Health, Inc. $546 26 payments
  11. Other $6,081 261 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,125 670 payments
  2. Consulting Fee $1,700 1 payment
  3. Travel and Lodging $865 3 payments
  4. Education $40 4 payments
Products named General payments · program years 2021–2025
  1. AFREZZA $3,005 26 payments
  2. Dexcom G6 Transmitter $1,418 47 payments
  3. Korlym $1,114 49 payments
  4. Ozempic $1,067 57 payments
  5. RYBELSUS $774 52 payments
  6. TEPEZZA $702 20 payments
  7. Kerendia $671 31 payments
  8. Wegovy $516 20 payments
  9. EVENITY $509 21 payments
  10. Prolia $419 20 payments
  11. Other $10,090 475 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

144

Median for Physician Assistant: 241

Drug cost

$107,670

Median for Physician Assistant: $4,110

Branded share of claims

42.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 27 $44,613
Mounjaro Tirzepatide Brand 15 $32,961
Jardiance Empagliflozin Brand 19 $29,444
Levothyroxine Sodium Generic 41 $334
Rosuvastatin Calcium Generic 15 $120
Atorvastatin Calcium Generic 11 $108
Metformin Hcl Generic 16 $92

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $510
$510 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $239
$239 — —
Wegovy
  • Novo Nordisk Inc $205
$205 — —
JARDIANCE
  • Lilly USA, LLC $132
  • Boehringer Ingelheim Pharmaceuticals, Inc. $18
$150 19 —
ISTURISA
  • RECORDATI_RARE_DISEASES_INC. $141
$141 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

678 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record